Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2015 2
2017 1
2018 1
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M. Hsu J, et al. Among authors: nicolai cj. J Clin Invest. 2018 Oct 1;128(10):4654-4668. doi: 10.1172/JCI99317. Epub 2018 Sep 10. J Clin Invest. 2018. PMID: 30198904 Free PMC article.
Millikelvin-resolved ambient thermography.
Tang K, Dong K, Nicolai CJ, Li Y, Li J, Lou S, Qiu CW, Raulet DH, Yao J, Wu J. Tang K, et al. Among authors: nicolai cj. Sci Adv. 2020 Dec 9;6(50):eabd8688. doi: 10.1126/sciadv.abd8688. Print 2020 Dec. Sci Adv. 2020. PMID: 33298452 Free PMC article.
Killer cells add fire to fuel immunotherapy.
Nicolai CJ, Raulet DH. Nicolai CJ, et al. Science. 2020 May 29;368(6494):943-944. doi: 10.1126/science.abc2502. Science. 2020. PMID: 32467380 No abstract available.
Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors.
Farley DC, McCloskey L, Thorne BA, Tareen SU, Nicolai CJ, Campbell DJ, Bannister R, Stewart HJ, Pearson LJ, Moyer BJ, Robbins SH, Zielinski L, Kim T, Radcliffe PA, Mitrophanous KA, Gombotz WR, Miskin JE, Kelley-Clarke B. Farley DC, et al. Among authors: nicolai cj. Mol Ther Methods Clin Dev. 2015 May 13;2:15017. doi: 10.1038/mtm.2015.17. eCollection 2015. Mol Ther Methods Clin Dev. 2015. PMID: 26029728 Free PMC article.
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
Odegard JM, Kelley-Clarke B, Tareen SU, Campbell DJ, Flynn PA, Nicolai CJ, Slough MM, Vin CD, McGowan PJ, Nelson LT, Ter Meulen J, Dubensky TW Jr, Robbins SH. Odegard JM, et al. Among authors: nicolai cj. J Immunother. 2015 Feb-Mar;38(2):41-53. doi: 10.1097/CJI.0000000000000067. J Immunother. 2015. PMID: 25658613 Free PMC article.
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
Tareen SU, Kelley-Clarke B, Nicolai CJ, Cassiano LA, Nelson LT, Slough MM, Vin CD, Odegard JM, Sloan DD, Van Hoeven N, Allen JM, Dubensky TW Jr, Robbins SH. Tareen SU, et al. Among authors: nicolai cj. Mol Ther. 2014 Mar;22(3):575-587. doi: 10.1038/mt.2013.278. Epub 2013 Dec 6. Mol Ther. 2014. PMID: 24419083 Free PMC article.